When PharmAthene Inc. merges with Seattle-based Theraclone Sciences Inc., it will become part of a company that has the kind of deal with Big Pharma any drug discovery firm would envy.
Theraclone has a multimillion dollar research and development deal with pharmaceutical giant Pfizer Inc. that could be worth as much as $632 million in license, royalty and other payments to the combined company. Theraclone and PharmAthene are entering into an all-stock merger of equals. The combined company will trade publicly.